Hematologic Malignancies

Dr Shadman
Videos
Dr Shadman Reviews Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant, R/R B-Cell Malignancies
01/10/2022
Mayzar Shadman, MD, MPH, Seattle Cancer Care Alliance, highlights phase 2 Study of zanubrutinib in BTK Inhibitor-Intolerant patients with relapsed/refractory B-Cell malignancies, presented at the 2021 ASH Annual Meeting.
Mayzar Shadman, MD, MPH, Seattle Cancer Care Alliance, highlights phase 2 Study of zanubrutinib in BTK Inhibitor-Intolerant patients with relapsed/refractory B-Cell malignancies, presented at the 2021 ASH Annual Meeting.
Mayzar Shadman, MD, MPH, Seattle...
01/10/2022
Oncology
Videos
John Byrd, MD, Discusses Acalabrutinib vs Ibrutinib for Patients With CLL
06/09/2021
Dr Byrd shares results from a phase 3 trial on acalabrutinib versus ibrutinib for patients with CLL. These data are being presented at the 2021 ASCO Annual Meeting.
Dr Byrd shares results from a phase 3 trial on acalabrutinib versus ibrutinib for patients with CLL. These data are being presented at the 2021 ASCO Annual Meeting.
Dr Byrd shares results from a...
06/09/2021
Oncology
Videos
KTE-X19 CAR-T Therapy Demonstrates Clinical Benefit for R/R B-ALL
06/08/2021
In part 1 of this video series, Bijal Shah, MD, shares results from the phase 2 ZUMA-3 study of KTE-X19 for R/R B-ALL. These data were presented at the 2021 ASCO Annual Meeting.
In part 1 of this video series, Bijal Shah, MD, shares results from the phase 2 ZUMA-3 study of KTE-X19 for R/R B-ALL. These data were presented at the 2021 ASCO Annual Meeting.
In part 1 of this video series,...
06/08/2021
Oncology
Dr Kastritis
Videos
Dr Kastritis Discusses Adding Daratumumab to Standard Therapy in AL Amyloidosis
06/08/2021
Efstathios Kastritis, MD, shares findings from the ANDROMEDA study of subcutaneous daratumumab combined with standard therapy in patients with AL amyloidosis.
Efstathios Kastritis, MD, shares findings from the ANDROMEDA study of subcutaneous daratumumab combined with standard therapy in patients with AL amyloidosis.
Efstathios Kastritis, MD, shares...
06/08/2021
Oncology
dr martin
Podcasts
Improvements in the Treatment of Patients With MCL Over the Past Decade
06/07/2021
Peter Martin, MD, discusses various treatment patterns and outcomes of patients with MCL over the past 10 years; these data were presented at the 2021 ASCO Annual Meeting.
Peter Martin, MD, discusses various treatment patterns and outcomes of patients with MCL over the past 10 years; these data were presented at the 2021 ASCO Annual Meeting.
Peter Martin, MD, discusses...
06/07/2021
Oncology
Podcasts
Ponatinib Dosing Regimen Demonstrates Improved Responses, Survival in Patients With CP-CML
06/04/2021
Jorge Cortes, MD, shares findings from the OPTIC trial on a dosing regimen of ponatinib for patients with CP-CML. These data are being presented at the 2021 ASCO Annual Meeting.
Jorge Cortes, MD, shares findings from the OPTIC trial on a dosing regimen of ponatinib for patients with CP-CML. These data are being presented at the 2021 ASCO Annual Meeting.
Jorge Cortes, MD, shares...
06/04/2021
Oncology
News
Pevonedistat Added to Azacitidine Promising for Higher-Risk MDS
01/12/2021
Pevonedistat plus azacitidine yields comparable safety to azacitidine monotherapy and demonstrates improvements in OS, EFS, and response rates in patients with higher-risk MDS.
Pevonedistat plus azacitidine yields comparable safety to azacitidine monotherapy and demonstrates improvements in OS, EFS, and response rates in patients with higher-risk MDS.
Pevonedistat plus azacitidine...
01/12/2021
Oncology
Autologous Transplantation for Relapsed DLBCL in the CAR-T Therapy Era
Videos
Autologous Transplantation for Relapsed DLBCL in the CAR-T Therapy Era
10/07/2020
Mehdi Hamadani, MD, discusses an analysis evaluating the role of autologous transplant in relapsed DLBCL with newer therapies, specifically CAR T-cells.
Mehdi Hamadani, MD, discusses an analysis evaluating the role of autologous transplant in relapsed DLBCL with newer therapies, specifically CAR T-cells.
Mehdi Hamadani, MD, discusses an...
10/07/2020
Oncology
News
Michael Mauro, MD, Talks ELN/NCCN Recommendations for Patients With CML
07/18/2020
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates &...
07/18/2020
Oncology
Recommended Phase 2 Dosing of Venetoclax Plus DA-EPOCH-R for B-Cell Lymphomas
Videos
Recommended Phase 2 Dosing of Venetoclax Plus DA-EPOCH-R for B-Cell Lymphomas
07/08/2020
Sarah Rutherford, MD, discusses the results from a phase 1 study, which evaluated the combination of venetoclax and DA-EPOCH-R for aggressive B-cell lymphomas.
Sarah Rutherford, MD, discusses the results from a phase 1 study, which evaluated the combination of venetoclax and DA-EPOCH-R for aggressive B-cell lymphomas.
Sarah Rutherford, MD, discusses...
07/08/2020
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use